• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·3164.TW
Share

GenMont Biotech Incorporation Stocks

NT$ 16.3Last Updated 28.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 43.64M

NT$ 16.3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Taiwan, GenMont Biotech Incorporation is primarily engaged in the comprehensive process of developing, manufacturing, and marketing functional probiotic products. Beyond its core offerings, the company also provides specialized probiotic formulations. It extends its services to include original formula design and production for health-oriented food items, as well as supplying relevant manufacturing equipment. Additionally, GenMont Biotech actively collaborates on the research, production, and clinical evaluation of a variety of other products. The company was established in 2000 and has its headquarters situated in Tainan City, Taiwan.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA, overval

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 19:40

"A Pure Expression of Power": How Christopher Nolan's "Odyssey" Will Change IMAX

28.07.2026 19:12

The Nasdaq 100 has entered a correction phase. The "Wall Street fear" index jumped

28.07.2026 18:30

Southern Japan has been hit by the strongest earthquake in 10 years. TSMC and Sony have factories there.

28.07.2026 17:57

The dollar index has stabilized near a four-week high ahead of the Fed's decision

28.07.2026 17:30

Mercedes has lowered its forecast due to a decline in demand for luxury models. Why did its stock price jump?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026